http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chung Ee-Yung,Lee C-Hang-Hoon,Park Ki-Ho 한국발생생물학회 2001 한국발생생물학회 학술발표대회 Vol.2001 No.-
R. Philippinarum is dioecious and oviparous. In the early vitellogenic oocyte, the Golgi apparatus and mitochondria present in the perinuclear region are involved in the formation of lipid droplets and in lipid granule formation. In the late vitellogenic oocyte, the endoplasmic reticulum, mitochondria in the cytoplasm are involved in the formation of proteid yolk granules. At this time, exogenous lipid granular substance and glycogen particles in the germinal epithelium are passed into the ooplasm of oocyte through the microvilli of the vitelline envelope. Ripe oocytes are about 55-60 m in diameter. The spawning period was once a year between early June and early October, and the main spawning occurred between July and August when seawater temperature was approximately 20 C. The reproductive cycle of this species can be categorized into five successive stages: early active stage (February to March), late active stage (April to May), ripe stage (April to August), partially spawned stage (June to October), and spent/inactive stage (August to March). Gonad developmental phases by histological qualitative analysis showed similar results with those of quantitative image analysis.
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Bang, Yung-Jue,Kang, Yoon-Koo,Kang, Won K.,Boku, Narikazu,Chung, Hyun C.,Chen, Jen-Shi,Doi, Toshihiko,Sun, Yan,Shen, Lin,Qin, Shukui,Ng, Wai-Tong,Tursi, Jennifer M.,Lechuga, Maria J.,Lu, Dongrui Ray,R Springer US 2011 Investigational new drugs Vol.29 No.6
<P><B>Summary</B></P><P><I>Purpose.</I> This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. <I>Experimental design</I>. Patients received sunitinib 50 mg/day on Schedule 4/2 (4 weeks on treatment, followed by 2 weeks off treatment). The primary endpoint was objective response rate; secondary endpoints included clinical benefit rate, duration of response, progression-free survival (PFS), overall survival (OS), pharmacokinetics, pharmacodynamics, safety and tolerability, and quality of life. <I>Results</I>. Of 78 patients enrolled, most had gastric adenocarcinoma (93.6%) and metastatic disease (93.6%). All were evaluable for safety and efficacy. Two patients (2.6%) had partial responses and 25 patients (32.1%) had a best response of stable disease for ≥6 weeks. Median PFS was 2.3 months (95% confidence interval [CI], 1.6–2.6 months) and median OS was 6.8 months (95% CI, 4.4–9.6 months). Grade ≥3 thrombocytopenia and neutropenia were reported in 34.6% and 29.4% of patients, respectively, and the most common non-hematologic adverse events were fatigue, anorexia, nausea, diarrhea, and stomatitis. Pharmacokinetics of sunitinib and its active metabolite were consistent with previous reports. There were no marked associations between baseline soluble protein levels, or changes from baseline, and measures of clinical outcome. <I>Conclusions</I>. The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunitinib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.</P>
Inhibition of Plaque Formation on the Titanium Surface by Anti-bacterial Varnish
정현주,이상현,김영준,Chung, Hyun-Ju,Lee, Sang-Hyun,Kim, Yung-Jun,Williams, Ray C. The Korean Academy of Periodontoloy 2000 Journal of Periodontal & Implant Science Vol.30 No.4
매식된 인공치아의 성공을 위해서는 적절한 교합과 수동적 적합성을 갖는 보철물의 제작과 구강내 노출 직후부터의 세균성 치태조절이 요구된다. 본 연구는 전처리(passivation과 tridodecyl - methyl - ammonium chloride(TDMAC) 처리)가 다른 타이타늄 표 면에 chlorhexidine varnish와 테트라사이클린 을 도포시 약제의 방출역학을 알아보고 구강내 치태형성의 억제정도를 평가하기 위하여 시행 되었다. 이를 위해 방출용액으로 인산완충액 성분의 인조타액을 1일${\sim}$1개월간 매일 교환하여 약제농도를 측정하고 타이타늄 박막에 잔류한 약제 활성을 측정하였으며 항균제 도포한 타이타늄 원판을 부착한 장치를 구강내 위치시킨 1일${\sim}$3주 후 원판을 제거하여 주사전자현미경으로 세균 부착상을 관찰하였다. 테트라사이클린은 TDMAC 처리된 표면에서 $10{\sim}18$일까지 유효농도로 방출되었고 표면의 유효 항균 활성은 $3{\sim}4$주간 유지되었으며, chlorhexidine varnish 도포 시에는 TDMAC 전처리시 초기에 $3{\sim}7$일 간 증가한 유효 항균 활성을 방출하여 매식지대치 등에 이러한 항균제도포 시 매식치 주위환경에 항균활성 공급원으로 작용할 수 있음을 보였다. 주사현미경적 관찰시 모든 타이타늄 표면에서 구강내 위치 30분 후에는 세균이 부착되어 있지 않고 타액 단백질 성분에서 유래한 것으로 보이는 피막물질이 표면을 부분 또는 전면에 걸쳐 덮고 있었다. 구강내 노출 2시간 후 항균제 미도포 표본들에는 약간의 구균이 단층으로, $1{\sim}3$일 후에는 부분적으로 두꺼운 세균층을 형성하였고 7일 후에는 표면전체에 걸쳐 세균층이 덮여있었으며 주로 구균과 약간의 간균이 주종을 이루었다. 항균제 도포시 구강내 노출 1주일 이전까지는 미도포군에 비해 치태형성이 지연되는 경향을 보였지만 2주 이후에는 세균 수나 치태형성 양상이 유사하였다. 이 연구로부터 항균제 도포시 1주일 이전의 초기 치태형성을 감소시킬 수 있음을 알 수 있었으며 이러한 연구결과는 타이타늄 임프란트 지대치 표면에 항균제의 도포가 임상적으로 유용할 수 있음을 시사하였다.
The Performance Study of a Virtualized Multicore Web System
( Chien-te Lu ),( C. -s. Eugene Yeh ),( Yung-chung Wang ),( Chu-sing Yang ) 한국인터넷정보학회 2016 KSII Transactions on Internet and Information Syst Vol.10 No.11
Enhancing the performance of computing systems has been an important topic since the invention of computers. The leading-edge technologies of multicore and virtualization dramatically influence the development of current IT systems. We study performance attributes of response time (RT), throughput, efficiency, and scalability of a virtualized Web system running on a multicore server. We build virtual machines (VMs) for a Web application, and use distributed stress tests to measure RTs and throughputs under varied combinations of virtual cores (VCs) and VM instances. Their gains, efficiencies and scalabilities are also computed and compared. Our experimental and analytic results indicate: 1) A system can perform and scale much better by adopting multiple single-VC VMs than by single multiple-VC VM. 2) The system capacity gain is proportional to the number of VM instances run, but not proportional to the number of VCs allocated in a VM. 3) A system with more VMs or VCs has higher physical CPU utilization, but lower vCPU utilization. 4) The maximum throughput gain is less than VM or VC gain. 5) Per-core computing efficiency does not correlate to the quality of VCs or VMs employed. The outcomes can provide valuable guidelines for selecting instance types provided by public Cloud providers and load balancing planning for Web systems.
Chen, Jen-Shi,Chao, Yee,Bang, Yung-Jue,Roca, Enrique,Chung, Hyun C.,Palazzo, Felipe,Kim, Yeul H.,Myrand, Scott P.,Mullaney, Brian P.,Shen, Li J.,Linn, Carlos Lippincott Williams Wilkins, Inc. 2010 ANTICANCER DRUGS Vol.21 No.8
This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed--cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18–70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75 mg/m. In phase I, the initial dose of pemetrexed was 600 mg/m, escalated in 100 mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700 mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2–18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8–7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed--cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.
강영배,김상희,장환,김창섭,김종염,권영방,이영옥,박정문,정운익,김공식,신종백,Kang Yung-Bai,Kim S.H.,Jang H.,Kim C.S.,Kim J.Y.,Kwon Y.B.,Rhee Y.O.,Park J.M.,Chung U.I.,Kim K.S.,Shin J.B. 대한수의사회 1987 대한수의사회지 Vol.23 No.5
Outbreaks of foulbrood in honey bees rearing on Cheju Island(an apiary with 172 colonies) and in Pusan City(an apiary with 100 colonies) were reported in April, 1987. The disease striked on Cheju Island was identified as American foulbrood caused by Bacil
암퇘지에 있어서 체성장에 따른 혈청 성 Hormone 의 농도변화에 관한 연구
박창식,이규승,정영호,정영채 ( Chang S . Park,Kyu S . Lee,Yung H . Chung,Yung C . Chung ) 한국축산학회 1982 한국축산학회지 Vol.24 No.4
The present study was carried out to study the serum concentrations of peptide and steroid hormones from birth to 110㎏ in growing pigs. Six crossbred female pigs at diestrus were used for collection of blood samples at different weight. FSH, LH, prolactin, estradiol, progesterone and cortisol were assayed by radioimmunoassay methods. Serum FSH concentrations did not change from birth to 110㎏ body weight and were not detected below 1.3 mIU/㎖. LH concentrations ranged from 1.6 to 2.3mIU/㎖. They increased at 50㎏ body weight and remained quite constant thereafter. Prolactin concentrations ranged from 2.4 to 3.0 ng/㎖. Estradiol concentrations were significantly high (250.2 pg/㎖) at birth and then rapidly dropped at 15㎏ body weight and remained fairly constant (from 27.2 to 29.7 pg/㎖) thereafter. Progesterone concentrations ranged from 0.8 to 2.7 ng/㎖. They were 1.5ng/㎖ at birth and 0.8ng/㎖ at 15㎏ body Weight, and then increased to 2.4 ng/㎖ st 30㎏ body weight and remained fairly constant thereafter. Cortisol concentrations ranged from 26.8 to 65.2 ng/㎖. They rose from a low of 26.8 ng/㎖ at birth to high of 51.2 ng/㎖ at 50㎏ of body weight and then gradually increased to 65.2 ng/㎖ at 110㎏ body weight.